| (Values in U.S. Thousands) | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2017 |
| Sales | 52,353 | 39,778 | 35,358 | 29,214 | 22,121 |
| Sales Growth | +31.61% | +12.50% | +21.03% | +32.06% | +110.38% |
| Net Income | 2,434 | 971 | 793 | 2,960 | 5,707 |
| Net Income Growth | +150.62% | +22.43% | -73.20% | -48.13% | +740.52% |
Hamilton Thorne Ltd
(HTL.VN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Hamilton Thorne Ltd is engaged in providing precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. The company markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors. The company's customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments. It has single reporting segment being Engaged in Sales to the ART, Research and Cell Biology Markets.
Fiscal Year End Date: 12/31